共 50 条
Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study
被引:38
|作者:
Kim, Jae-Min
[1
]
Kim, Sung-Wan
[1
]
Stewart, Robert
[2
]
Kim, Seon-Young
[1
]
Yoon, Jin-Sang
[1
]
Jung, Sung-Won
[3
]
Lee, Min-Soo
[4
]
Yim, Hyeon-Woo
[5
]
Jun, Tae-Youn
[6
]
机构:
[1] Chonnam Natl Univ, Sch Med, Dept Psychiat, Kwangju 501757, South Korea
[2] Inst Psychiat, Epidemiol Sect, London, England
[3] Keimyung Univ, Sch Med, Dept Psychiat, Taegu, South Korea
[4] Korea Univ, Coll Med, Dept Psychiat, Seoul 136705, South Korea
[5] Catholic Univ Korea, Coll Med, Dept Prevent Med, Seoul, South Korea
[6] Catholic Univ Korea, Coll Med, Dept Psychiat, Seoul, South Korea
基金:
新加坡国家研究基金会;
关键词:
depression;
remission;
anxiety;
parasuicide;
Korea;
STAR-ASTERISK-D;
MAJOR DEPRESSION;
OUTPATIENTS;
SERTRALINE;
ANXIETY;
COMORBIDITY;
VENLAFAXINE;
CITALOPRAM;
RECOVERY;
SYMPTOMS;
D O I:
10.1002/hup.1168
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Objective To estimate the 12-week remission rate of patients with depressive disorders and predictors of this in a naturalistic clinical setting in South Korea. Methods For people with DSM-IV depressive disorders about to receive treatment at 18 hospitals, data on sociodemographic and health status were obtained. A free choice of clinical interventions was allowed and naturalistic follow-up took place at 1, 2, 4, 8, and 12 weeks later. Remission was defined as a Hamilton Depression Rating Scale score of <= 7 sustained to 12 weeks or last follow-up, if earlier. Results For 723 participants, the 12-week remission rate was 31.4%. Remission was more likely in women, and in patients without a prior history of suicide attempt, and those with lower baseline anxiety. Conclusions Remission associated with unrestricted clinical interventions was comparable to STAR*D estimates for citalopram alone. Comorbid anxiety and previous suicide attempt were markers of worse outcome. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:41 / 50
页数:10
相关论文